Compare Royal Bank of Canada (RY) vs Summit Therapeutics Inc (SMMT) Price & Performance

Royal Bank of Canada (RY) trades at $213.35, up 1.21% today, with a bullish technical signal and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $2.84 versus $2.81 expected, and a 30.6% net income margin in 2025 highlight robust profitability. The stock is supported by a dividend of $1.76 payable in August 2026 and positive analyst coverage, though insider selling and high valuation metrics warrant attention.

RY's outlook remains positive with projected 2026 revenue of $69.5B and net income of $22.1B, but risks include elevated P/E of 19.07, significant debt levels, and potential macroeconomic pressures on the banking sector. The stock offers steady growth and income, yet investors should weigh valuation concerns against strong operational trends.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.